New Drug Reviews
Empagliflozin (Jardiance) for Type 2 Diabetes Mellitus
Am Fam Physician. 2016 Dec 15;94(12):1014-1015.
Empagliflozin (Jardiance) is one of three approved sodium-glucose cotransporter 2 (SGLT2) inhibitors for type 2 diabetes mellitus. It lowers blood glucose by reducing reabsorption of glucose in the kidney, which leads to increased urinary excretion of glucose.
10 mg or 25 mg once daily
10- or 25-mg tablets
10 mg or 25 mg once daily
10- or 25-mg tablets
For all SGLT2 inhibitors, there have been rare postmarket case reports (less than 1%) of pyelonephritis, sepsis of urinary origin,1 and diabetic ketoacidosis without high blood glucose levels.2 Other rare serious adverse effects include hypovolemia and hypotension (number needed to harm [NNH] = 335). Although infrequent, severe hypoglycemia may occur in patients taking multiple-dose injection insulin. Mild or moderate hypoglycemia occurs most often when combining empagliflozin with any insulin and less often with sulfonylureas.3 No human studies have included pregnant or breastfeeding mothers.3 Empagliflozin is U.S. Food and Drug Administration pregnancy risk category C and should be avoided in the late second and third trimesters, during fetal renal development.
Empagliflozin is generally well tolerated, with no greater discontinuation rate than placebo. There is no difference in the risk of urinary tract infection between the treatment and placebo groups.4 However, women and men are both more prone to genital fungal infections while taking empagliflozin. Over three years of treatment, 10% of women (NNH = 14) and 5% of men (NNH = 29) report a genital mycotic infection.5 Empagliflozin can cause minor increases in low-density lipoprotein cholesterol levels, a small decrease (less than 5 mm Hg) in systolic blood pressure, and a slight increase in hematocrit levels, which typically do not warrant additional treatment.3
Empagliflozin may reduce mortality in patients with diabetes who are at high risk of cardiovascular death. One study that added empagliflozin or placebo to existing type 2 diabetes treatment (75% of participants were already taking metformin) in older patients with preexisting cardiovascular disease demonstrated lower all-cause mortality (5.7% vs. 8.3%; number needed to treat [NNT] = 38 over 3.3 years), cardiovascular mortality (3.7% vs. 5.9%; NNT = 45 over 3.3 years), and hospitalization for heart failure (2.7% vs. 4.1%; NNT = 71) in the empagliflozin group vs. the placebo group.5 However, empagliflozin is not approved by the U.S. Food and Drug Administration to decrease mortality in patients with cardiovascular disease. There are no long-term data on morbidity or mortality benefits in patients without preexisting cardiovascular disease, and this benefit has not been documented with other SGLT2 inhibitors.
Patients with type 2 diabetes who are taking empagliflozin will lose an average of 2% body weight (about 4.3 to 4.8 lb [1.94 to 2.16 kg]), and the medication will induce further weight loss in patients already treated with linagliptin (Tradjenta).
When used alone, empagliflozin decreases hemoglobin A1C levels by 0.7 to 0.9 percentage points, with only a small increase in effect with the higher dose. When added to other antidiabetic agents, empagliflozin produces an additional average A1C decrease of 0.6 percentage points. Its effectiveness decreases in patients with lower renal function, and it is not effective in patients with a glomerular filtration rate of less than 45 mL per minute.
The cost of a one-month supply of empagliflozin is approximately $410. This cost is similar to other SGLT2 inhibitors and is significantly more expensive than metformin or glipizide (Glucotrol), which both cost about $5 per month.
Empagliflozin is taken orally once daily as monotherapy or add-on therapy. The recommended starting dosage is 10 mg once per day, which can be increased to 25 mg once per day if A1C goals are not achieved, although, on average, the dosage increase will produce only minor A1C changes.
Empagliflozin can be added to existing type 2 diabetes treatment to lower A1C levels, although there are less expensive options. In older patients with preexisting cardiovascular disease, empagliflozin can decrease all-cause mortality, cardiovascular mortality, and hospitalization for heart failure.
REFERENCESshow all references
1. U.S. Food and Drug Administration. SGLT2 inhibitors: drug safety communication—labels to include warnings about too much acid in the blood and serious urinary tract infections. December 4, 2015. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm475553.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery. Accessed July 6, 2016....
2. Health Canada. Summary safety review—SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin)—assessing the risk of the body producing high levels of acids in the blood (diabetic ketoacidosis). May 16, 2016. http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/sglt2-2-eng.php. Accessed July 6, 2016.
3. DailyMed. Label: Jardiance—empagliflozin tablet, film coated. Updated July 11, 2016. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=faf3dd6a-9cd0-39c2-0d2e-232cb3f67565. Accessed July 6, 2016.
4. Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG Outcome Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
5. U.S. Food and Drug Administration. Endocrinologic and metabolic drugs advisory committee briefing document. EMPA-REG outcome trial. May 19, 2016. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM508423.pdf. Accessed July 8, 2016.
STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.
This series is coordinated by Allen F. Shaughnessy, PharmD, MMedEd, Contributing Editor.
A collection of STEPS published in AFP is available at https://www.aafp.org/afp/steps.
Copyright © 2016 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
May 15, 2019
Access the latest issue of American Family Physician